Xeris Biopharma Holdings Inc (fra:2B30) Share Price

Company Profile

Business description
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Contact
1375 West Fulton Street
Suite 1300
ChicagoIL60607
USA
T: +1 844 445-5704
E: [email protected]
https://www.xerispharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
435

Recommended

The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.

Jacob Robbins | 11 June 2026

We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.

Seth Goldstein, CFA | 11 June 2026

How to avoid the dividend aristocrat trap.

Susan Dziubinski | 10 June 2026

Index	Last price	Change	% Change
All Ordinaries	8,836.70	71.20	0.81%
CAC 40	8,200.80	38.97	0.48%
DAX 40	24,209.71	14.40	0.06%
Dow JONES (US)	50,848.75	929.97	1.86%
FTSE 100	10,303.88	49.07	0.48%
HKSE	24,249.29	158.67	-0.65%
NASDAQ	25,809.66	640.16	2.54%
Nikkei 225	64,217.27	38.00	0.06%
NZX 50 Index	13,269.70	67.54	0.51%
S&P 500	7,394.30	127.31	1.75%
S&P/ASX 200	8,633.20	69.70	0.81%
SSE Composite Index	3,987.01	6.21	-0.16%